drugset / Trial / NCT00715793
Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
NaSingle-groupOpen-labelTreatment
Summary
The combination of TMZ and DAC may effect dual modulation of DNA repair genes resulting in improved clinical response.
Timeline
- Start
- 2008-06
- Primary completion
- 2015-05
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 0.075 mg/kg | Intravenous |
| Subject | Decitabine | Small molecule | 0.15 mg/kg | Intravenous |
| Subject | Temozolomide | Small molecule | 75 mg/m2 | Oral |